Article
Pharmacogenetics in the Treatment of Pre-Eclampsia: Current Findings, Challenges and Perspectives
30 Mar 2017
Abstract excerpt
Pre-eclampsia (PE) is defined as pregnancy-induced hypertension and proteinuria, and is a major cause of maternal and perinatal morbidity and mortality. A large subgroup of pregnant women with PE is nonresponsive to antihypertensive drugs, including methyldopa, nifedipine and hydralazine. Pharmacogenomics may help to guide the individualized therapy for this nonresponsive subgroup. However, just a few...
Topics
Join the communities discussing this publication.